Basic Information
| LncRNA/CircRNA Name | ODRUL |
| Synonyms | FOXC2-AS1, ODRUL |
| Region | GRCh38_16:86565145-86567761 |
| Ensemble | ENSG00000260944 |
| Refseq | NR_125795 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | doxorubicin | ||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | osteosarcoma |
| ICD-0-3 | NA |
| Methods | qPCR, Microarray, Western blot, Luciferase reporter assay etc. |
| Sample | cell lines (SaoS2, HOS, U2-OS, MG63, 143B) |
| Expression Pattern | up-regulated |
| Function Description | ODRUL is upregulated in OS tissues and cell lines and correlates with poor prognosis. A microarray screen combined with online database analysis showed that miR-3182 is upregulated and MMP2 is downregulated in sh-ODRUL-expressing MG63 cells and that miR-3182 harbors potential binding sites for ODRUL and the 30 UTR of MMP2 mRNA. In addition, miR-3182 expression and function are inversely correlated with ODRUL expression in vitro and in vivo. A luciferase reporter assay demonstrated that ODRUL could directly interact with miR-3182 and upregulate MMP2 expression via its competing endogenous RNA activity on miR-3182 at the posttranscriptional level. |
| Pubmed ID | 28750740 |
| Year | 2017 |
| Title | LncRNA ODRUL Contributes to Osteosarcoma Progression through the miR-3182/MMP2 Axis |
External Links
| Links for ODRUL | GenBank HGNC NONCODE |
| Links for osteosarcoma | OMIM COSMIC |